These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 17197126)

  • 1. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer.
    Liu YM; Shiau CY; Lee ML; Huang PI; Hsieh CM; Chen PH; Lin YH; Wang LW; Yen SH
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1113-23. PubMed ID: 17197126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
    Ashman JB; Zelefsky MJ; Hunt MS; Leibel SA; Fuks Z
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):765-71. PubMed ID: 15913914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
    Lee CT; Dong L; Ahamad AW; Choi H; Cheung R; Lee AK; Horne DF; Breaux AJ; Kuban DA
    Am J Clin Oncol; 2005 Dec; 28(6):618-25. PubMed ID: 16317275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy.
    Lujan AE; Mundt AJ; Yamada SD; Rotmensch J; Roeske JC
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):516-21. PubMed ID: 12957265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.
    Roeske JC; Lujan A; Rotmensch J; Waggoner SE; Yamada D; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1613-21. PubMed ID: 11121668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMRT to escalate the dose to the prostate while treating the pelvic nodes.
    Cavey ML; Bayouth JE; Colman M; Endres EJ; Sanguineti G
    Strahlenther Onkol; 2005 Jul; 181(7):431-41. PubMed ID: 15995836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
    Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
    Yoo S; Wu QJ; Lee WR; Yin FF
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):935-42. PubMed ID: 20044214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.
    Georg P; Georg D; Hillbrand M; Kirisits C; Pötter R
    Radiother Oncol; 2006 Jul; 80(1):19-26. PubMed ID: 16766068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.